The Centers for Medicare and Medicaid Services has announced a new initiative to provide reimbursement for PET when patients and physicians participate in high-quality clinical studies or submit information to a PET data registry. The announcement heralds a move away from PET coverage decisions on an indication by indication basis.
The Centers for Medicare and Medicaid Services has announced a new initiative to provide reimbursement for PET when patients and physicians participate in high-quality clinical studies or submit information to a PET data registry. The announcement heralds a move away from PET coverage decisions on an indication by indication basis.
The move would allow coverage for PET use in previously uncovered applications such as the evaluation of patients with cervical, brain, pancreatic, ovarian, and testicular cancers.
"This is a very innovative decision on the part of CMS. In essence, they would be providing provisional coverage for PET in a variety of applications, with permanent coverage pending results of clinical trials and evaluation of the data registry," said Dr. Bruce Hillman, chair of the American College of Radiology Imaging Network.
One of the more important aspects of this move is the decision to tie reimbursement to a national data registry, according to Hillman. The registry will be managed by ACRIN and the Academy of Molecular Imaging. Participating referring physicians would submit surveys electronically to the ACRIN archives both before and after PET scans, providing a national database for PET applications.
Reimbursing PET outside of clinical trials would depend on the amount of data and research that radiologists and other interested physicians provide for the data registry, he said. The more radiologists and physicians participate in the program and the more data are submitted to the registry, the faster an indication could be approved for reimbursement.
National PET data collection would allow ACRIN and AMI researchers to evaluate the effectiveness of PET for a variety of indications and to determine whether the modality had any effect on a referring physician's clinical decisions.
Determination of just how the registry will work and will be set up is under way, Hillman said. Medicare coverage for new indications will go into effect when the final registry is implemented later this spring.
"One of the major outcomes of CMS's decision is that patients will now have access to PET who would not have had access under the previous method of reimbursement," he said.
For more information from the online Diagnostic Imaging archives:
Medicare begins PET Alzheimer's reimbursement
PET/CT profitability hinges on building the market
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.